Minnema, M.C.

patient reactivation response relapse treatment transplantation thalidomide blood cycle cell transplantation survival month allogeneic group study myeloma disease perforin fi rst cycle azacitidine perforin expression maintenance lenalidomide analysis donor signi figure therapy graft allogeneic nma sct range number allo-sct expression signi ficantly marrow infection platelet autologou cmv infection result table factor dexamethasone 1000 copies /ml erasmus mc percentage autologous sct netherland criteria trial department response rate randomized patients randomized transplant recipient incidence grade progression follow-up effect azacitidine treatment virus perforin-expressing prognostic center cmv-positive induction blast level increase count allogeneic sct ficantly platelet count ef ficacy protocol utrecht lenalidomide maintenance